Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#3036 Can Ki-67 with 5.5% Be Better in Predicting Prognosis for Well Differentiated Pancreatic Neuroendocrine Tumors?

Introduction: Pancreatic neuroendocrine tumors (NETs) are rare malignancies, Ki-67 is a cell proliferation marker that has been shown to have some utility in predicting prognosis of neuroendocrine tumors. However, the ideal grading method for G1/G2 remains controversial.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Tan H

Authors: Yuan B, Chen Y, Zhang P, Wang X, Tan H,

Keywords: Pancreatic net, G1, G2, Ki-67, overall survival time,

#3034 Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Is There Any Benefit When Ki-67 Is ≥ 10%?

Introduction: The antiproliferative effect of first-line long acting somatostatin analogs (SSA) in advanced gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) was shown in the PROMID and the CLARINET trials. Efficacy data in pancreatic NETs (PanNETs) with Ki-67 ≥ 10% are limited.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Merola E

Authors: Merola E, Alonso Gordoa T, Zhang P, Al-Toubah T, Pelle E,

Keywords: Pancreatic NET, Somatostatin Analogs, Grade 2 and 3, Safety, Efficacy,

#3026 IMP3 and Ki-67-Factors of Poor Clinical Outcome in Neuroendocrine Tumors of the Lung

Introduction: Insulin- like growth factor-II messenger RNA- binding protein- 3 (IMP3) is often detected in malignant neoplasm of different sites. Ki-67 proliferative index, although helpful in diagnosing neuroendocrine tumours of lung, has not been recognised as prognostic factor.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Bełz A, Stęplewska K, Głogowska- Szeląg J,

Keywords: carcinoid, IMP3, Ki-67, neuroendocrine,

#2997 Benefits of 177Lu-DOTATATE in Patients with Advanced Neuroendocrine Tumours: Case Reports from Two Patients with High Disease Burden

Introduction: In the NETTER-1 study, peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE increased progression-free survival (PFS) and time to deterioration in quality of life (QoL) in patients with advanced midgut neuroendocrine tumours (NETs), compared with octreotide.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Wadsley J, Shah T,

Keywords: 177Lu-DOTATATE, metastases, quality of life,

#2951 Analysis of Discordance between Biopsy Grade and Surgical Pathology Grade in Resected PanNEN Patients

Introduction: In PanNEN cases, treatment strategies are decided by tumor localization, volume and grade. In unresectable or metastatic cases, tumor grade is determined by biopsy specimen obtained from EUS-FNA and diagnostic accuracy of biopsy according to WHO classification 2017 is important for decision making of treatment.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Nakano K, Masui T, Yogo A, Uchida Y, Nagai K,

Keywords: PanNEN, WHO classification 2017, EUS-FNA, Ki-67, biopsy, surgical pathology, discordance,